312 related articles for article (PubMed ID: 20693850)
41. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
42. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
43. Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer.
Foster AE; Forrester K; Li YC; Gottlieb DJ
Curr Pharm Des; 2004; 10(11):1207-20. PubMed ID: 15078136
[TBL] [Abstract][Full Text] [Related]
44. Harnessing Dendritic Cells for Poly (D,L-lactide-
Koerner J; Horvath D; Groettrup M
Front Immunol; 2019; 10():707. PubMed ID: 31024545
[TBL] [Abstract][Full Text] [Related]
45. An artificial solution for adoptive immunotherapy.
Zemon H
Trends Biotechnol; 2003 Oct; 21(10):418-20. PubMed ID: 14512224
[No Abstract] [Full Text] [Related]
46. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
Wank R; Song X; Gu S; Laumbacher B
Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
[TBL] [Abstract][Full Text] [Related]
47. Tumor immunotherapy: cytokines and antigen presentation.
Lord EM; Frelinger JG
Cancer Immunol Immunother; 1998 Apr; 46(2):75-81. PubMed ID: 9558002
[TBL] [Abstract][Full Text] [Related]
48. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
[No Abstract] [Full Text] [Related]
49. Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.
Kosmides AK; Meyer RA; Hickey JW; Aje K; Cheung KN; Green JJ; Schneck JP
Biomaterials; 2017 Feb; 118():16-26. PubMed ID: 27940380
[TBL] [Abstract][Full Text] [Related]
50. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
51. Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.
Schütz C; Fleck M; Schneck JP; Oelke M
J Vis Exp; 2014 Aug; (90):e51859. PubMed ID: 25145915
[TBL] [Abstract][Full Text] [Related]
52. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
[TBL] [Abstract][Full Text] [Related]
53. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
54. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
[TBL] [Abstract][Full Text] [Related]
55. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
56. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.
Hasan AN; Selvakumar A; Doubrovina E; Riviere I; Sadelain MW; O'Reilly RJ
Discov Med; 2009 Dec; 8(43):210-8. PubMed ID: 20040272
[TBL] [Abstract][Full Text] [Related]
57. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
Yannelli JR; Wroblewski JM
Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
[TBL] [Abstract][Full Text] [Related]
58. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
59. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming.
Arina A; Tirapu I; Alfaro C; Rodríguez-Calvillo M; Mazzolini G; Inogés S; López A; Feijoo E; Bendandi M; Melero I
Exp Hematol; 2002 Dec; 30(12):1355-64. PubMed ID: 12482496
[TBL] [Abstract][Full Text] [Related]
60. Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.
Wang C; Sun W; Ye Y; Bomba HN; Gu Z
Theranostics; 2017; 7(14):3504-3516. PubMed ID: 28912891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
